• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email
    SC 13G/A 1 wp-sc13ga_093024.htm AMENDMENT TO FORM SC13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

     

    Sotera Health Company  

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share  

    (Title of Class of Securities)

     

    83601L 102  

    (CUSIP Number)

     

    September 30, 2024  

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

     

    CUSIP No. 83601L 102 Page 2 of 25

       
    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    WP XI, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.3% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the U.S. Securities and Exchange Commission (“Commission”) September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

    CUSIP No. 83601L 102 Page 3 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Private Equity XI, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

    CUSIP No. 83601L 102 Page 4 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus XI Partners, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission on September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

    CUSIP No. 83601L 102 Page 5 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Private Equity XI-B, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 6 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Private Equity XI-C, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

    CUSIP No. 83601L 102 Page 7 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Bull Co-Invest, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 8 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Private XI, L.P. 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 9 of 25

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    WP Global LLC 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (a) ☐ (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12

    TYPE OF REPORTING PERSON

     

    OO 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 10 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Partners II, L.P. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH: 

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2)

    12  

    TYPE OF REPORTING PERSON

     

    PN

                   

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.
                 

     

     

     

    CUSIP No. 83601L 102 Page 11 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Partners GP LLC 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH: 

      5  

    SOLE VOTING POWER

     

    0

      6  

    SHARED VOTING POWER

     

    123,038,253 (1)

      7  

    SOLE DISPOSITIVE POWER

     

    0

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2)

    12  

    TYPE OF REPORTING PERSON

     

    OO

                   

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

    CUSIP No. 83601L 102 Page 12 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus & Co. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York 

                 

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

     EACH

    REPORTING

     PERSON

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12  

    TYPE OF REPORTING PERSON

     

    PN 

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 13 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus (Cayman) XI, L.P. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH: 

    5  

    SOLE VOTING POWER

     

    0 

    6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

    7  

    SOLE DISPOSITIVE POWER

     

    0 

    8  

    SHARED DISPOSITIVE POWER

     

    73,822,952  

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253  

    10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12  

    TYPE OF REPORTING PERSON

     

    PN 

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 14 of 25

     

    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus XI-C, LLC 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH: 

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12  

    TYPE OF REPORTING PERSON

     

    OO 

    (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.
    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 15 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus Partners II (Cayman), L.P. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH: 

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12  

    TYPE OF REPORTING PERSON

     

    PN 

                   

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.
                 

     

     

     

    CUSIP No. 83601L 102 Page 16 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus (Bermuda) Private Equity GP, Ltd. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda 

                 

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY

     EACH

    REPORTING

     PERSON

    WITH:

      5  

    SOLE VOTING POWER

     

    0 

      6  

    SHARED VOTING POWER

     

    123,038,253 (1) 

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2)

    12  

    TYPE OF REPORTING PERSON

     

    PN

                   

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2) Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

     

    CUSIP No. 83601L 102 Page 17 of 25

                 
    1  

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Warburg Pincus LLC 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☒

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

                 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH: 

      5  

    SOLE VOTING POWER

     

    0

      6  

    SHARED VOTING POWER

     

    123,038,253 (1)

      7  

    SOLE DISPOSITIVE POWER

     

    0 

      8  

    SHARED DISPOSITIVE POWER

     

    73,822,952 

                 
    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    123,038,253 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    43.4% (2) 

    12  

    TYPE OF REPORTING PERSON

     

    OO 

                   

     (1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G, the WP Investors are party to a Stockholders Agreement with the GTCR Investors and certain other holders of Common Stock of the Issuer. The WP Investors, together with the GTCR Investors, hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), of which 49,215,301 shares of Common Stock are publicly reported as being owned by the GTCR Investors in such entities’ Form 4, filed with the Commission September 9, 2024. Although the WP Reporting Persons may be deemed to beneficially own the Common Stock held as of record by the GTCR Investors as a result of the Stockholders Agreement, each WP Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock other than the shares of Common Stock of the Issuer owned of record by such WP Reporting Person. The percentages herein have been determined in accordance with footnote 2 below. Capitalized terms used herein are defined in Items 2(a) or 4 below.

    (2)

    Calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

     

     

    CUSIP No. 83601L 102 Page 18 of 25

     

    Item 1(a). Name of Issuer:

     

    The name of the issuer is Sotera Health Company, a Delaware corporation (the “Issuer”).

     

    Item 1(b). Address of the Issuer’s Principal Executive Offices:

     

    The principal executive offices of the Issuer are located at 9100 South Hills Blvd, Suite 300 Broadview Heights, OH 44147.

     

    Item 2(a). Names of Persons Filing:

     

    This Amendment No. 2 to Schedule 13G is being filed jointly by Warburg Pincus XI, L.P., a Delaware limited partnership ("WP XI GP"), is the general partner of each of (i) Warburg Pincus Private Equity XI, L.P. ("WP XI"), (ii) Warburg Pincus Private Equity XI-B, L.P. ("WP XI-B"), (iii) WP XI Partners, L.P. ("WP XI Partners") and (iv) Warburg Pincus XI Partners, L.P. ("Warburg Pincus XI Partners"). WP Global LLC ("WP Global"), is the general partner of WP XI GP. Warburg Pincus Partners II, L.P. ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC ("WPP GP LLC"), is the general partner of WPP II. Warburg Pincus & Co. ("WP"), is the managing member of WPP GP LLC. Warburg Pincus (Cayman) XI, L.P. ("WP XI Cayman GP"), is the general partner of Warburg Pincus Private Equity XI-C, L.P. ("WP XI-C" and, together with WP XI, WP XI-B, WP XI Partners and Warburg Pincus XI Partners, the "WP XI Funds"). The WP XI Funds, Bull Co-Invest, Bull Holdco, WP Global, WPP II, WPP GP LLC, WP XI Cayman GP, WP XI-C LLC, WPP II Cayman, WP Bermuda GP, WP Bull Manager, WP LLC and WP are collectively referred to herein as the "Warburg Pincus Entities."

     

    Warburg Pincus XI-C, LLC ("WP XI-C LLC"), is the general partner of WP XI Cayman GP. Warburg Pincus Partners II (Cayman), L.P. ("WPP II Cayman"), is the managing member of WP XI-C LLC. Warburg Pincus (Bermuda) Private Equity GP Ltd. ("WP Bermuda GP"), is the general partner of WPP II Cayman. WP Bull Manager LLC ("WP Bull Manager"), is the general partner of Bull Co-Invest. WP is managing member of WP Bull Manager. Warburg Pincus LLC, a New York limited liability company ("WP LLC"), is the manager of the WP XI Funds. The WP XI Funds share limited partnership ownership in Bull Holdco on a pro rata basis in accordance with their respective numbers of Contributed Shares. The WP XI Funds, Bull Co-Invest, WP XI-C, WP XI LP, WP Global, WPP II, WPP GP LLC, WP Cayman, Warburg Pincus XI-C, WPP II Cayman, Warburg Pincus (Bermuda), WP Bull Manager, WP LLC and WP are collectively referred to herein as the “Warburg Pincus Reporting Persons or WP Investors.”

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Warburg Pincus Reporting Persons is 450 Lexington Avenue, New York, New York 10017.

     

    Item 2(c). Citizenship:

     

    See Item 2(a).

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.01 per share (the “Common Stock”).

     

    Item 2(e). CUSIP Number:

     

    83601L 102

     

     

     

     

    CUSIP No. 83601L 102 Page 19 of 25

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

      ☒ Not applicable

     

      (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

     

      (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

     

      (e) ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). 

     

      (f) ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F). 

     

      (g) ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). 

     

      (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).

     

      (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3). 

     

      (j) ☐ Non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J). 

     

      (k) ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution:   

     

    Item 4. Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto for each Warburg Pincus Reporting Person and is incorporated herein by reference for each such Warburg Pincus Reporting Person.

     

    On November 19, 2020, (i) the Issuer, (ii) Warburg Pincus Private Equity XI, L.P., Warburg Pincus Private Equity XI_B, L.P., Warburg Pincus Private Equity XI-C, L.P., WP XI Partners, L.P. and Bull Co-Invest (collectively, the “Warburg Pincus Sponsors”), (iii) GTCR Fund XI/A LP, GTCR Fund XI/C LP, and GTCR Co-Invest XI LP. (collectively, the “GTCR Funds”) and (iv) certain other holders of Common Stock of the issuer ( the “Other Investors”), entered into a Stockholders Agreement (the “Stockholders Agreement”). The Stockholders Agreement sets forth certain governance arrangements with respect to the Issuer, transfer restrictions on Other Investors and indemnification matters. Pursuant to the Stockholders Agreement, each of the Warburg Pincus Sponsors and the GTCR Funds has agreed to vote the shares of Common Stock of the Issuer that each holds of record in a certain manner on matters related to the election of certain directors appointed by the Warburg Pincus Sponsors and the GTCR Sponsors. The Warburg Pincus Sponsors and the GTCR Sponsors hold an aggregate total of 123,038,253 shares of Common Stock of the Issuer (approximately 43.4% of the outstanding shares of Common Stock of the Issuer), including 49,215,301 shares of Common Stock of the Issuer that are publicly reported as being owned by the GTCR Sponsors and 73,822,952 shares of Common Stock of the Issuer that are publicly reported as being owned by the Warburg Pincus Reporting Persons. The Warburg Pincus Reporting Persons are not entitled to any rights as a shareholder of the Issuer with respect to the shares of Common Stock of the Issuer beneficially owned by the Other Investors or the GTCR Sponsors except as expressly set forth in the Stockholders Agreement and the Warburg Pincus Reporting Persons do not have dispositive power over the Common Stock owned by the GTCR Sponsors. Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the Issuer owned of record by such Warburg Pincus Reporting Person. The number of shares of Common Stock of the Issuer owned by each Warburg Pincus Reporting Person as set forth in Rows 5 – 11 of their respective cover pages to this Schedule 13G does not reflect the aggregate shares of Common Stock of the Issuer owned by the Other Investors.

     

     

     

     

    CUSIP No. 83601L 102 Page 20 of 25

     

    The aggregate total of 49,215,301 shares of Common Stock of the Issuer indicated in this Amendment No. 2 to Schedule 13G as being beneficially owned by the GTCR Sponsors is derived from the GTCR Sponsors’ Form 4, filed with the Commission on September 9, 2024, and is not purported to be an accurate representation of the GTCR Sponsors’ beneficial ownership as of the date of this Amendment No. 2 to Schedule 13G. The GTCR Sponsors are responsible for reporting their beneficial ownership of shares of Common Stock of the Issuer on their own behalf, and the Warburg Pincus Reporting Persons disclaim responsibility for reporting the shares of Common Stock of the Issuer beneficially owned by the GTCR Sponsors.

     

    The percentages used herein are calculated based on 283,214,342 shares of Common Stock outstanding as of July 29, 2024 as reported on the Issuer’s final prospectus reported on Form 424B7, filed on September 5, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Other than as set forth herein, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, in excess of 5% of the total outstanding Common Stock.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    (1) The Warburg Pincus Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of the Exchange Act. The joint filing agreement among the Warburg Pincus Reporting Persons to file this Amendment No. 2 to Schedule 13G jointly in accordance with Rule 13d-1(k) of the Exchange Act is incorporated by reference as Exhibit 99.1.

     

    (2) Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the issuer owned of record by such Warburg Pincus Reporting Person.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certification.

     

    Not Applicable.

     

     

     

     

    CUSIP No. 83601L 102 Page 21 of 25

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

           
      WARBURG PINCUS PRIVATE EQUITY XI, L.P.
       
      By: Warburg Pincus XI, L.P., its general partner
       
      By: WP Global LLC, its general partner
       
      By: Warburg Pincus Partners II, L.P., its managing member
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti  

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS XI PARTNERS, L.P.
       
      By: Warburg Pincus XI, L.P., its general partner
       
      By: WP Global LLC, its general partner
       
      By: Warburg Pincus Partners II, L.P., its managing member
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS PRIVATE EQUITY XI-B, L.P.
       
      By: Warburg Pincus XI, L.P., its general partner
       
      By: WP Global LLC, its general partner
       
      By: Warburg Pincus Partners II, L.P., its managing member
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner

     

     

     

     

    CUSIP No. 83601L 102 Page 22 of 25

           
      WP XI Partners, L.P.
       
      By: Warburg Pincus XI, L.P., its general partner
       
      By: WP Global LLC, its general partner
       
      By: Warburg Pincus Partners II, L.P., its managing member
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS PRIVATE EQUITY XI-C, L.P.
       
      By: Warburg Pincus (Cayman) XI, L.P., its general partner
       
      By: Warburg Pincus XI-C, LLC, its general partner
       
      By: Warburg Pincus Partners II (Cayman), L.P., its managing member
       
      By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Authorised Signatory
       
      BULL CO-INVEST L.P.
       
      By: WP Bull Manager LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS XI, L.P.
       
      By: WP Global LLC, its general partner
       
      By: Warburg Pincus Partners II, L.P., its managing member
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner

     

     

     

     

    CUSIP No. 83601L 102 Page 23 of 25

           
      WP GLOBAL LLC
       
      By: Warburg Pincus Partners II, L.P., its managing member
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS PARTNERS II, L.P.
       
      By: Warburg Pincus Partners GP LLC, its general partner
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS PARTNERS GP LLC
       
      By: Warburg Pincus & Co., its managing member
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS & CO.
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Partner
       
      WARBURG PINCUS (CAYMAN) XI, L.P.
       
      By: Warburg Pincus XI-C, LLC, its general partner
       
      By: Warburg Pincus Partners II (Cayman), L.P., its managing member
       
      By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Authorised Signatory

     

     

     

     

    CUSIP No. 83601L 102 Page 24 of 25

           
      WARBURG PINCUS XI-C, LLC
       
      By: Warburg Pincus Partners II (Cayman), L.P., its managing member
       
      By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Authorised Signatory
       
      WARBURG PINCUS PARTNERS II (CAYMAN), L.P.
       
      By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Authorised Signatory
       
      WARBURG PINCUS (BERMUDA) PRIVATE EQUITY GP LTD.
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Authorised Signatory
       
      WARBURG PINCUS LLC
         
      By:  

    /s/ Harsha Marti 

      Name:   Harsha Marti
      Title:   Managing Director

     

     

     

    CUSIP No. 83601L 102 Page 25 of 25

     

    EXHIBIT LIST

     

    Exhibit 99.1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.*
       

    * Incorporated herein by reference to the Agreement of Joint Filing by Warburg Pincus Private Equity XI, L.P., Warburg Pincus XI Partners, L.P., Warburg Pincus Private Equity XI-B, L.P., WP XI Partners, L.P., Warburg Pincus Private Equity XI-C, L.P., Bull Co-Invest L.P., Warburg Pincus XI, L.P., WP Global LLC, Warburg Pincus Partners II, L.P., Warburg Pincus Partners GP LLC, Warburg Pincus & Co., Warburg Pincus (Cayman) XI, L.P., Warburg Pincus XI-C, LLC, Warburg Pincus Partners II (Cayman), L.P., Warburg Pincus (Bermuda) Private Equity GP LTD., and Warburg Pincus LLC (“Warburg Pincus Funds”) dated as of February 14, 2022, which was previously filed with the Commission as Exhibit 99.1 to Amendment No. 1 to Schedule 13G filed by the Warburg Pincus Funds on February 14, 2022 with respect to the shares of common stock of Sotera Health Co.

     

     

    Get the next $SHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $SHC
    Financials

    Live finance-specific insights

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

      2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

      2/27/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

      CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

      1/6/25 4:30:38 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Petras Michael B. Jr. covered exercise/tax liability with 100,849 shares and was granted 298,953 shares, increasing direct ownership by 30% to 868,603 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 9:49:47 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • President of Sterigenics Rutz Michael P covered exercise/tax liability with 13,284 shares and was granted 48,579 shares, increasing direct ownership by 7% to 576,815 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:38:48 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 6,481 shares and was granted 97,159 shares, increasing direct ownership by 82% to 201,110 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:36:07 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

      SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe. Nelson Labs' testing solution is unique in that it supports a broad range of both medical devices and pharmaceutical products. This innovative approach broadens the scope of Rapid Sterility Testing—a field that has primarily focused on products with biological components or short shelf life—by providing a vers

      3/4/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:51:55 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:50:09 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/12/24 5:53:58 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Goldman initiated coverage on Sotera Health with a new price target

      Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

      12/6/24 8:14:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Piper Sandler initiated coverage on Sotera Health with a new price target

      Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

      5/21/24 7:45:20 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      5/2/25 4:05:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Sotera Health Company

      10-Q - Sotera Health Co (0001822479) (Filer)

      5/1/25 4:05:19 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      5/1/25 7:45:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care